Trial reportRheumatology international2011
Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus.
Trial report in Rheumatology international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Effectiveness and safety of tacrolimus in systemic lupus erythematosus with various clinical manifestations: a retrospective real-world study.Arthritis research & therapy · 2025Article
- Efficacy of tacrolimus and other immunosuppressants in the treatment of systemic lupus erythematosus: A systematic review and meta-analysis.Biomedical reports · 2025Article
- Efficacy of Tacrolimus Plus Prednisone as Long-Term Immunosuppressive Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective Cohort Study.ImmunoTargets and therapy · 2025Article
- Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.Lupus science & medicine · 2024Review
- Tacrolimus shows adequate efficacy in patients with antiphospholipid antibodies associated thrombocytopenia: a retrospective cohort study.Clinical and experimental medicine · 2023Article
- Review
- Efficacy and steroid-sparing effect of tacrolimus in patients with autoimmune cytopenia.Annals of hematology · 2022Article
- Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.Clinical rheumatology · 2019Article
- Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres.Lupus science & medicine · 2018Article
- Calcineurin Inhibitors in the Treatment of Lupus Nephritis: A Hare Versus Turtle Story?Journal of the American Society of Nephrology : JASN · 2017Article
- Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study.Lupus science & medicine · 2015Article
- Treatment of young patients with lupus nephritis using calcineurin inhibitors.World journal of nephrology · 2012Review
- Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases.Mediators of inflammation · 2012Review
- Improvement of irregularity of brain vessel walls in systemic lupus erythematosus by tacrolimus.Clinical rheumatology · 2011Article
- Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis.Open access rheumatology : research and reviews · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N=21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.